ZURA BIO
Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as ZB-168 and torudokimab, with auto-immune illnesses. ZB-168 is an anti-IL7R inhibitor that may have an effect on disorders whose biological pathways are IL7 and TSLP. They create therapeutic indications for ZB-168 that build on the type 1 diabetes data from Phase 1b studies and show a profile and biological basis. The phase 2 clinical development stage of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33, has been established.
ZURA BIO
Industry:
Biopharma Biotechnology Medical
Founded:
2022-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.zurabio.com
Total Employee:
11+
Status:
Active
Contact:
1-858-247-0520
Email Addresses:
[email protected]
Total Funding:
192.5 M USD
Technology used in webpage:
Euro Content Delivery Network HSTS JsDelivr CrUX Dataset BootstrapCDN JQuery CDN CrUX Top 10m COVID-19 OVH
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Clementia Pharmaceuticals
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Sitari Pharmaceuticals
Sitari Pharmaceuticals is a biotechnology company developing treatments for multiple disease indications.
Symvivo Corporation
Symvivo Corporation is a clinical-stage biotechnology company that develops DNA vaccines for genetic and life-threatening diseases.
Trestle Biotherapeutics
Trestle Biotherapeutics is a biotechnology company that introduces bioengineered kidneys for patients with kidney disease.
Zylem Biosciences
Zylem Biosciences is a startup biotechnology company developing targeted medicines that uniquely mimic features of natural biologics.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Allostery Investments
Allostery Investments investment in Post-IPO Equity - Zura Bio
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Zura Bio
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Zura Bio
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Zura Bio
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Zura Bio
Access Biotechnology
Access Biotechnology investment in Post-IPO Equity - Zura Bio
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Zura Bio
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Zura Bio
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Zura Bio
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Zura Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-08 | Zura Bio Announces Robert Lisicki as CEO and Director |
| 2024-03-28 | Zura Bio names Robert Lisicki as CEO, succeeding Someit Sidhu, M.D. |
| 2023-04-14 | Zura Bio Announces Appointment of Chief Scientific Officer |
Official Site Inspections
http://www.zurabio.com Semrush global rank: 4.23 M Semrush visits lastest month: 2.35 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zura Bio"
About Us - Zura Bio
Our team, composed of industry experts and asset-hunters, leverages a dual antagonism strategy to target multiple mechanisms or pathways simultaneously, thereby potentially increasing the โฆSee details»
Zura Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 1-858-247-0520 Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as โฆSee details»
Building the Next Immunology Leader - Zura Bio Ltd
Zura Bio Limited (Nasdaq: ZURA) | LinkedIn
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which ...See details»
Zura Bio Limited (ZURA) Company Profile & Facts - Yahoo Finance
See the company profile for Zura Bio Limited (ZURA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives โฆSee details»
Zura Bio Continues to Strengthen Leadership with Appointment of โฆ
Organization as we initiate multiple Phase 2 clinical trials in 2024. Rob and Kiran have dedicated much of their careers to delivering results across ... [email protected] Source: Zura Bio โฆSee details»
Zura Bio Limited (ZURA) Company Profile & Overview - Stock โฆ
Dec 3, 2024 Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv โฆSee details»
Zura Bio Company Profile - Office Locations, Competitors ... - Craft
Aug 21, 2024 Zura Bio is company a clinical-stage biotechnology company advancing immunology assets into development programs. It aims to develop a portfolio of therapeutic โฆSee details»
Zura Bio to Participate in Two Upcoming Investor Conferences in ...
Oct 30, 2024 HENDERSON, Nev.--(BUSINESS WIRE)--Oct. 30, 2024-- Zura Bio Limited (Nasdaq: ZURA) (โZura Bioโ), a clinical stage, multi-asset immunology company developing โฆSee details»
Zura Bio - Overview, News & Similar companies | ZoomInfo.com
Jan 3, 2024 Zura Bio contact info: Phone number: (858) 247-0520 Website: www.zurabio.com What does Zura Bio do? Founded in 2022 and headquartered in San Diego, California, โฆSee details»
Pipeline - Zura Bio
Zura Bio is focused on the development of therapies in challenging immunological conditions by deeply interrogating the therapeutic mechanism of action and pairing that with those patients โฆSee details»
Zura Bio Reports Third Quarter 2024 Financial Results and Recent ...
HENDERSON, Nev., November 07, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for โฆSee details»
Release Details - Zura Bio Ltd
Jun 6, 2023 Tibulizumab (ZB-106) was licensed from Eli Lilly and Company on April 26, 2023; Total cash and cash equivalents of approximately $120 million is expected to fund planned โฆSee details»
ZB-106 - Zura Bio
Systemic sclerosis is a rare and potentially fatal autoimmune disease characterized by tissue inflammation and fibrosis. Globally, there are approximately 200,000 individuals affected, with โฆSee details»
Release Details - Zura Bio Ltd
Aug 8, 2024 HENDERSON, Nev.--(BUSINESS WIRE)--Aug. 9, 2024-- Zura Bio Limited (Nasdaq: ZURA) (โZura Bioโ or the โCompanyโ), a clinical-stage immunology company โฆSee details»
Zura Bio Limited - Cruelty Free Investing
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual โฆSee details»
ZB-168 - Zura Bio
Crebankitug (ZB-168) is a fully human-IgG1 monoclonal antibody targeted against the IL-7Rฮฑ, which plays a key role in the development, function and homeostasis of T cells. We believe โฆSee details»
Release Details - Zura Bio Ltd
Mar 21, 2023 Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology; Business combination results in approximately $65 million in gross โฆSee details»
ZB-880 - Zura Bio
References. IL-33: Roles in Allergic Inflammation and Therapeutic Perspectives Chan BCL, Lam CWK, Tam L-S and Wong CK (2019) Front. Immunol. 10:364. doi: 10.3389/fimmu.2019.00364 โฆSee details»
Release Details - Zura Bio Ltd
Jun 17, 2022 Company advancing ZB-168, an anti-IL7Rฮฑ monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials. The transaction values the โฆSee details»